|Bid||163.10 x 100|
|Ask||163.29 x 200|
|Day's Range||161.53 - 163.47|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||15.51|
|Dividend & Yield||4.60 (2.79%)|
|1y Target Est||N/A|
Amgen's top-selling anti-inflammatory drug, Enbrel, may have already hit its high-water mark.
The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need.
Q1 2017 Amgen Inc Earnings Call